• Live
    • Audio Only
  • google plus
  • facebook
  • twitter
  • Imprimis Pharmaceuticals announced Oct. 22 that it plans to sell an alternative to Daraprim for less than US$1 a capsule.

    Imprimis Pharmaceuticals announced Oct. 22 that it plans to sell an alternative to Daraprim for less than US$1 a capsule. | Photo: Reuters

Published 22 October 2015

The company is promising to undercut a much-hated rival that was blasted by doctors and patients for making a rare life-saving drug unaffordable.

A U.S. pharmaceutical company is promising to sell for less than US$1 a capsule as an alternative to a life-saving drug that made headlines last month after its sole producer jacked up the price by more than 550 percent.

On Thursday, the San Diego-based drug company Imprimis announced that it would be selling Daraprim, used primarily to treat infections suffered by those with immune systems weakened by HIV/AIDS and pregnancy, for “as low as US$99.00 for a 100 count bottle.”

The announcement comes after The New York Times reported last month that Turing Pharmaceuticals, headed by 32-year-old Martin Shkreli, had purchased Daraprim and immediately increased the price from US$13.50 to US$750. The article noted that Shkreli had done it before, as have many other manufacturers of generic drugs in the United States.

“This isn’t the greedy drug company trying to gouge patients, it is us trying to stay in business,” Shkreli told the Times.

Most people saw it otherwise. Shkreli received a torrent of criticism on social media. U.S. presidential candidate Hillary Clinton called the price hike “outrageous.” Her rival, U.S. Senator Bernie Sanders, refused Shkreli’s US$2,700 campaign donation, giving it to a health clinic instead.

RELATED: Sanders Tells Big Pharma Mogul Shkreli: 'We Don't Want Your Stinking Money'

On Twitter, Shkreli has remained defiant, insisting that he is not mad about all the negative publicity but actually finds it all funny.

Shkreli did respond to a request for comment from teleSUR English.

Tags

Drugs Health
Comment
0
Comments
Post with no comments.